Nivolumab (targeting PD-1), pembrolizumab (targeting PD-1) and atezolizumab (targeting PD-L1) are examples of blocking antibodies to overcome this regulatory blockade during cancer treatment, in combination with other regimens. This evidence concerns the gene CD274 and cancer.